News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
40 Under 40
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
52,449 Results
Type
Article (2137)
Company Profile (5)
Press Release (50307)
Section
Business (24945)
Career Advice (33)
Deals (3387)
Drug Delivery (4)
Drug Development (5318)
Employer Resources (6)
FDA (1038)
Job Trends (1196)
News (33093)
Policy (1836)
Tag
Academia (90)
Accelerated approval (1)
Adcomms (1)
Allergies (6)
Alliances (1643)
ALS (7)
Alzheimer's disease (90)
Antibody-drug conjugate (ADC) (13)
Approvals (1068)
Artificial intelligence (17)
Automation (2)
Bankruptcy (11)
Best Places to Work (1200)
BIOSECURE Act (1)
Biosimilars (8)
Biotechnology (2)
Bladder cancer (6)
Brain cancer (3)
Breast cancer (38)
Cancer (250)
Cardiovascular disease (23)
Career advice (31)
Career pathing (1)
CAR-T (6)
Cell therapy (28)
Cervical cancer (4)
Clinical research (4791)
Collaboration (32)
Compensation (19)
Complete response letters (1)
COVID-19 (166)
CRISPR (2)
C-suite (4)
Cystic fibrosis (8)
Data (331)
Depression (4)
Diabetes (29)
Diagnostics (576)
Digital health (2)
Diversity, equity & inclusion (3)
Drug discovery (10)
Drug pricing (7)
Duchenne muscular dystrophy (6)
Earnings (22767)
Editorial (1)
Employer branding (1)
Employer resources (6)
Events (4770)
Executive appointments (12)
FDA (1224)
Frontotemporal dementia (3)
Funding (29)
Gene editing (5)
Gene therapy (12)
GLP-1 (47)
Government (221)
Guidances (80)
Healthcare (1552)
IgA nephropathy (7)
Immunology and inflammation (14)
Indications (6)
Infectious disease (184)
Inflammatory bowel disease (5)
Influenza (3)
Intellectual property (3)
Interviews (3)
IPO (2697)
Job creations (101)
Job search strategy (29)
Kidney cancer (3)
Labor market (3)
Layoffs (17)
Legal (303)
Liver cancer (4)
Lung cancer (50)
Lymphoma (24)
Manufacturing (13)
MASH (23)
Medical device (1352)
Medtech (1352)
Mergers & acquisitions (737)
Metabolic disorders (85)
Multiple sclerosis (14)
NASH (7)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (143)
NextGen: Class of 2025 (384)
Non-profit (141)
Now hiring (1)
Obesity (35)
Opinion (3)
Ovarian cancer (4)
Pain (7)
Pancreatic cancer (6)
Parkinson's disease (7)
Partnered (2)
Patents (8)
Patient recruitment (5)
Peanut (4)
People (1515)
Pharmaceutical (3)
Phase I (999)
Phase II (1847)
Phase III (2233)
Pipeline (484)
Policy (5)
Postmarket research (228)
Preclinical (354)
Prostate cancer (16)
Radiopharmaceuticals (33)
Rare diseases (29)
Real estate (166)
Recruiting (3)
Regulatory (1499)
Reports (4)
Research institute (101)
Resumes & cover letters (1)
Rett syndrome (1)
RSV (2)
Schizophrenia (11)
Series A (3)
Series B (2)
Service/supplier (1)
Sickle cell disease (4)
Special edition (1)
Spinal muscular atrophy (16)
Sponsored (1)
Startups (111)
Stomach cancer (3)
Supply chain (2)
Tariffs (2)
Vaccines (65)
Weight loss (17)
Women's health (2)
Worklife (1)
Date
Today (16)
Last 7 days (180)
Last 30 days (375)
Last 365 days (3818)
2025 (1432)
2024 (4123)
2023 (4620)
2022 (5180)
2021 (5163)
2020 (4887)
2019 (3298)
2018 (2515)
2017 (2228)
2016 (1581)
2015 (2308)
2014 (1565)
2013 (1054)
2012 (1155)
2011 (1234)
2010 (1169)
Location
Africa (36)
Alabama (25)
Alaska (1)
Arizona (7)
Asia (2880)
Australia (884)
California (768)
Canada (223)
China (43)
Colorado (30)
Connecticut (28)
Delaware (17)
Europe (6931)
Florida (145)
Georgia (29)
Idaho (6)
Illinois (42)
India (1)
Indiana (39)
Japan (25)
Kansas (6)
Kentucky (3)
Louisiana (4)
Maine (12)
Maryland (85)
Massachusetts (460)
Michigan (24)
Minnesota (35)
Missouri (9)
Montana (3)
Nevada (9)
New Hampshire (9)
New Jersey (284)
New York (252)
North Carolina (94)
Northern California (374)
Ohio (13)
Pennsylvania (198)
Rhode Island (2)
South America (61)
Southern California (283)
Tennessee (4)
Texas (83)
United States (2752)
Utah (24)
Virginia (9)
Washington D.C. (1)
Washington State (48)
Wisconsin (4)
52,449 Results for "96".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Petros Pharmaceuticals Announces Pricing of $9.6 Million Public Offering of Common Stock and Warrants
February 18, 2025
·
5 min read
Press Releases
Akero Therapeutics Presents Week 96 Results from Phase 2b SYMMETRY Clinical Trial of Efruxifermin in Patients with Compensated Cirrhosis Caused by MASH Showing Fibrosis Improvement without Worsening of MASH at the EASL Congress 2025
May 9, 2025
·
8 min read
Press Releases
CareDx Announces District Court Reverses Jury Decision in Patent Infringement Case Overturning Prior $96 Million Verdict
February 25, 2025
·
3 min read
Nectero Medical Announces Completion of $96M Series D Financing
Nectero Medical today announced the closing of its $96 million Series D financing round.
April 11, 2024
·
4 min read
U.S. Biotechnology Market Size to Hit USD 1,785.96 Billion By 2033
According to Vision Research Reports, the U.S. biotechnology market size was valued at USD 552.43 billion in 2023 and is anticipated to hit around USD 1,785.96 billion by 2033, growing at a CAGR of 12.45% from 2024
May 2, 2024
·
10 min read
Press Releases
Long Read Sequencing Market Size Boosts 30.96% Solid CAGR to Hit USD 11.60 Billion by 2034
December 12, 2024
·
1 min read
Press Releases
Akero Therapeutics to Present Preliminary Topline Week 96 Results from Phase 2b SYMMETRY Study Investigating Efruxifermin in Patients with Compensated Cirrhosis (F4) Due to MASH
January 24, 2025
·
5 min read
Drug Development
Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study
Akero Therapeutics, Inc. released preliminary topline week 96 results from HARMONY, a Phase 2b study evaluating the efficacy and safety of its lead product candidate efruxifermin in patients with pre-cirrhotic metabolic dysfunction-associated steatohepatitis, fibrosis stage 2 or 3.
March 4, 2024
·
12 min read
Business
Venatorx Pharmaceuticals and Menarini Group Enter Commercial Agreement for Cefepime-Taniborbactam in 96 Countries
Venatorx Pharmaceuticals and Menarini Group today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to commercialize, upon approval of relevant health authorities, cefepime-taniborbactam in 96 countries.
January 9, 2024
·
6 min read
Press Releases
Akero Therapeutics Reports Preliminary Topline Results Showing Statistically Significant Reversal of Compensated Cirrhosis (F4) Due to MASH—by Both Completer and ITT Analyses—at Week 96 in Phase 2b SYMMETRY Study
January 27, 2025
·
8 min read
1 of 5,245
Next
